Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660297 | 0.93 | CYP1A2 (0.53) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL357443 | 0.93 | CYP1A2 (0.53) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL28539881 | 0.90 | CYP1A2 (0.50) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| Ammonia Solution, Strong SCHEMBL2263911 | 0.90 | CYP1A2 (0.50) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL167933 | 0.86 | CYP1A2 (0.53) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL1834490 | 0.83 | TSHR (0.41) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL29379467 | 0.82 | CYP1A2 (0.56) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL377040 | 0.82 | CYP1A2 (0.56) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL1508302 | 0.81 | KDM4E (0.40) | CYP1A2TSHRCYP3A4HSD17B10HPGD | |
| Ammonia Solution, Strong SCHEMBL8197954 | 0.81 | TSHR (0.40) | CYP1A2TSHRCYP3A4HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343317-A1 | EXTRACTION OF CARBOXYLIC ACIDS FROM A DILUTE AQUEOUS STREAM | PURAC BIOCHEM B.V. (NL) | 2014-11-20 | — | — | US | disclosed |
| US-8101590-B2 | 9-aminocarbonylsubstituted derivatives of glycylcyclines | WYETH LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20050101656-A1 | 11-O-METHYLGELDANAMYCIN COMPOUNDS | KOSAN BIOSCIENCES, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| US-6887993-B1 | 11-O-methylgeldanamycin compounds | KOSAN BIOSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6855705-B1 | 11-O-methylgeldanamycin compounds | KOSAN BIOSCIENCES, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-5932596-A | NOVEL COMPOUNDS HAVING ANTAGONIST OR AGONIST ACTIVITY ON H3 RECEPTORS AND PHARMACEUTICAL COMPOSITIONS THEREOF; USE FOR TREATING DISORDERS INCLUDING ALLERGY, INFLAMMATION, HYPERTENSION, SLEEP DISORDERS, ALZHEIMER'S | SCHERING CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-4916137-A | 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders | AMERICAN CYANAMID COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049564-A1 | 9-Aminocarbonylsubstituted derivatives of glycylcyclines | Q6ZSR9, GMPS, RPS10 | CYP1A2 1427/4885TSHR 2245/4885CYP3A4 1273/4885 |
| US-20050101656-A1 | 11-O-METHYLGELDANAMYCIN COMPOUNDS | RPS11, RIOX2, CCNA1 | CYP1A2 1924/4885TSHR 2827/4885CYP3A4 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.